Equities Analysts Offer Predictions for Heron Therapeutics, Inc.’s Q1 2024 Earnings (NASDAQ:HRTX)

Heron Therapeutics, Inc. (NASDAQ:HRTX) – Research analysts at Capital One Financial issued their Q1 2024 earnings per share (EPS) estimates for shares of Heron Therapeutics in a report released on Tuesday, April 23rd. Capital One Financial analyst T. Chiang forecasts that the biotechnology company will post earnings per share of ($0.09) for the quarter. Capital One Financial currently has a “Overweight” rating and a $6.00 target price on the stock. The consensus estimate for Heron Therapeutics’ current full-year earnings is ($0.22) per share. Capital One Financial also issued estimates for Heron Therapeutics’ Q2 2024 earnings at ($0.07) EPS, Q3 2024 earnings at ($0.06) EPS, Q4 2024 earnings at ($0.05) EPS, FY2024 earnings at ($0.28) EPS, FY2025 earnings at ($0.06) EPS, FY2026 earnings at $0.16 EPS, FY2027 earnings at $0.33 EPS and FY2028 earnings at $0.47 EPS.

A number of other research analysts also recently issued reports on the company. StockNews.com upgraded Heron Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, January 16th. Needham & Company LLC reiterated a “buy” rating and issued a $5.00 price target on shares of Heron Therapeutics in a report on Thursday, April 11th.

Heron Therapeutics Trading Down 5.4 %

Shares of NASDAQ:HRTX opened at $2.65 on Thursday. Heron Therapeutics has a 12-month low of $0.50 and a 12-month high of $3.22. The business’s fifty day simple moving average is $2.75 and its 200-day simple moving average is $1.96. The company has a market capitalization of $398.37 million, a PE ratio of -3.08 and a beta of 1.68.

Heron Therapeutics (NASDAQ:HRTX) last announced its quarterly earnings results on Tuesday, March 12th. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.08. The company had revenue of $34.23 million during the quarter, compared to analysts’ expectations of $30.98 million.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. SG Americas Securities LLC purchased a new position in Heron Therapeutics during the 3rd quarter worth $31,000. Victory Capital Management Inc. grew its stake in Heron Therapeutics by 30.2% during the 4th quarter. Victory Capital Management Inc. now owns 19,929 shares of the biotechnology company’s stock valued at $34,000 after purchasing an additional 4,617 shares during the last quarter. ACT Advisors LLC. purchased a new stake in Heron Therapeutics during the 4th quarter valued at about $38,000. Dakota Wealth Management purchased a new stake in Heron Therapeutics during the 3rd quarter valued at about $55,000. Finally, Diversified Trust Co purchased a new stake in Heron Therapeutics during the 1st quarter valued at about $66,000. 80.01% of the stock is currently owned by hedge funds and other institutional investors.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.